Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

12 trials with published results (27%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

4.4%

2 terminated out of 45 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

22%

10 trials in Phase 3/4

Results Transparency

60%

12 of 20 completed with results

Key Signals

12 with results91% success

Data Visualizations

Phase Distribution

40Total
Not Applicable (13)
Early P 1 (1)
P 1 (1)
P 2 (15)
P 3 (4)
P 4 (6)

Trial Status

Completed20
Recruiting10
Unknown6
Active Not Recruiting3
Terminated2
Suspended2

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (45)

Showing 20 of 20 trials
NCT07172516Phase 3Recruiting

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT06560957Not ApplicableRecruiting

SYNCED - SYNChronized Eating in Bipolar Depression Study

NCT06696755Phase 2Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

NCT03484494Not ApplicableActive Not Recruiting

Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

NCT06184581Phase 4RecruitingPrimary

Lithium Versus Lamotrigine in Bipolar Disorder, Type II

NCT07217860Phase 3Enrolling By Invitation

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

NCT07213466Phase 4Recruiting

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT06804525Recruiting

LHC-CIDI-5 in Hong Kong

NCT05004896Phase 2Completed

Ketamine for Treatment-Resistant Bipolar Disorder

NCT05339074Phase 2Completed

Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

NCT05340686Not ApplicableSuspended

Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression

NCT05427123Recruiting

Children's Bipolar Network Treatment Trial I

NCT06605599Phase 2Completed

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

NCT05658510Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT07116694Phase 2Active Not Recruiting

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

NCT07127913Not ApplicableRecruitingPrimary

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression

NCT06706232Phase 2RecruitingPrimary

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

NCT05064319Phase 2Recruiting

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

NCT04211428Withdrawn

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder

NCT06129500Not ApplicableSuspended

CBT for Problematic Impulsive Behaviours in Bipolar Disorder: A Case Series / CBT-PIB

Scroll to load more

Research Network

Activity Timeline